Evidence map›Paper›PMID 40329139›Full record

ArticleAAPS PharmSciTech2025

Ethyl-Cellulose Nanosponges for Topical Delivery of Simvastatin with Preferential Skin Retention for Wound Healing in a Full-Thickness Wound Rat Model.

Samar Aboelazayem, Maha Nasra, Heba Ebada, Ossama Abdallah

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samar AboelazayemDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Maha NasraDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Heba EbadaCentral Lab, Faculty of Pharmacy, Damanhour University, Damanhour, 22511, Egypt. heba.m.khiry@gmail.com.ORCID http://orcid.org/0000-0003-1790-1385
Ossama AbdallahDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel topical nanosponges were implemented to improve the skin availability of simvastatin (SV) for treating full-thickness wounds while controlling the scarring process. SV exhibits great potential in treating various skin diseases owing to its antibacterial, antioxidant, anti-inflammatory, and immunomodulatory properties. However, its poor oral bioavailability and systemic side effects have hindered its clinical application in dermatology. For the first time, nanosponges were utilized to target injured skin, creating an SV reservoir within the wound bed to enhance therapeutic efficacy while minimizing adverse effects. Herein, SV-loaded ethyl-cellulose nanosponges (SV-NS) were prepared using the emulsion solvent evaporation technique, optimizing organic solvents, SV concentration, and stabilizer concentration. The selected SV-NS (20 mg SV) exhibited nanoporous particles (786.2 ± 50 nm), a specific surface area of 10.3 m

Indexed as

CelluloseNanoparticlesSimvastatinSkinWound HealingAdministration, CutaneousAdministration, TopicalAnimalsDisease Models, AnimalDrug Delivery SystemsDrug LiberationEmulsionsMaleNanostructuresRatsRats, Sprague-DawleyCelluloseEmulsionsethyl celluloseSimvastatinethyl-cellulose nanospongefull-thickness woundssimvastatinskin penetrationtopical

Identifiers

PMID40329139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.